Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19198881 | 0.76 | HSD17B3 (0.42) | HSD17B3TSHRLMNAMAPK1SCN4A | |
| SCHEMBL22297598 | 0.76 | LMNA (0.41) | HSD17B3TSHRLMNAMAPK1SCN4A | |
| SCHEMBL21308708 | 0.73 | HSD17B3 (0.54) | HSD17B3TSHRLMNAMAPK1SCN4A | |
| SCHEMBL21251610 | 0.73 | HSD17B3 (0.38) | HSD17B3TSHRLMNAMAPK1SCN4A | |
| SCHEMBL23255184 | 0.73 | HSD17B3 (0.38) | HSD17B3TSHRLMNAMAPK1SCN4A | |
| SCHEMBL22295672 | 0.72 | HSD17B3 (0.53) | HSD17B3TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL19067688 | 0.72 | HSD17B3 (0.39) | HSD17B3TSHRLMNAMAPK1SCN4A | |
| SCHEMBL19733706 | 0.72 | P2RX4 (0.41) | HSD17B3TSHRLMNAMAPK1SCN4A | |
| SCHEMBL24455244 | 0.72 | HSD17B3 (0.39) | HSD17B3TSHRLMNAMAPK1SCN4A | |
| SCHEMBL22601433 | 0.72 | CHRM2 (0.40) | HSD17B3TSHRLMNAMAPK1SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183147-A1 | CARRIER-PROTEIN POLYSACCHARIDE CONJUGATION METHODS | VAXCYTE, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2022270549-A1 | NOVEL POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | 持田製薬株式会社 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022145419-A1 | MULTILAYER STRUCTURE USING CHEMICALLY CROSSLINKED ALGINIC ACID | 持田製薬株式会社 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022136705-A1 | GLYCAN-CONJUGATED ANTIBODIES BINDING TO FC-GAMMA RECEPTOR | SYNAFFIX B.V. (NL) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022120476-A1 | AMATOXIN ANALOGS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-16 | — | — | WO | disclosed |
| EP-3991792-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022040266-A1 | CARRIER-PROTEIN POLYSACCHARIDE CONJUGATION METHODS | VAXCYTE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2021125255-A1 | NOVEL CROSSLINKED ALGINIC ACID | 持田製薬株式会社 | 2021-06-24 | — | — | WO | disclosed |
| EP-3183345-B1 | BIOCOMPATIBLE INFINITE COORDINATION POLYMER NANOPARTICLE-NUCLEIC ACID CONJUGATES FOR ANTISENSE GENE REGULATION | UNIV NORTHWESTERN (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20210123057-A1 | Sequence Multiplicity Within Spherical Nucleic Acids | NORTHWESTERN UNIVERSITY | 2021-04-29 | — | — | US | disclosed |
| EP-3812376-A1 | PACLITAXEL-LIPID-POLYSACCHARIDE DUAL-TYPE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Santolecan Pharmaceuticals LLC (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3183007-B1 | PROTEIN/OLIGONUCLEOTIDE CORE-SHELL NANOPARTICLE THERAPEUTICS | UNIV NORTHWESTERN (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2018089373-A9 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018089373-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183147-A1 | CARRIER-PROTEIN POLYSACCHARIDE CONJUGATION METHODS | DDOST, STT3B, STT3A | HSD17B3 3670/4885TSHR 3547/4885LMNA 2498/4885 |
| US-20210123057-A1 | Sequence Multiplicity Within Spherical Nucleic Acids | TLR9, SRRT, MICA | HSD17B3 4795/4885TSHR 1782/4885LMNA 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.